Brainsway
Brainsway is the developer of Deep Transcranial Magnetic Stimulation (TMS) Therapy, a patented, noninvasive, FDA-cleared solution for treating depressive episodes in adult patients suffering from major depressive disorder who have failed to achieve s.
Launch date
Employees
Market cap
$128m
Enterprise valuation
$83m (Public information from Sep 2024)
Share price
$8.4 BWAY
Burlington Massachusetts (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 23.1m | 22.1m | 29.7m | 27.2m | 31.8m | 39.7m | 46.2m |
| % growth | 41 % | (5 %) | 34 % | (8 %) | 17 % | 25 % | 16 % |
| EBITDA | (6.6m) | (4.8m) | (3.3m) | (11.1m) | (2.5m) | - | - |
| % EBITDA margin | (28 %) | (22 %) | (11 %) | (41 %) | (8 %) | - | - |
| Profit | (10.3m) | (5.4m) | (6.5m) | (13.3m) | (4.2m) | - | - |
| % profit margin | (45 %) | (24 %) | (22 %) | (49 %) | (13 %) | - | - |
| R&D budget | 7.9m | 5.8m | 6.4m | 7.7m | 6.7m | - | - |
| R&D % of revenue | 34 % | 26 % | 22 % | 28 % | 21 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | $27.5m | IPO |
| N/A | $45.2m | Post IPO Equity | |
| Total Funding | - | ||
Related Content
Recent News about Brainsway
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.